CSTF2

Across TCGA pan-cancer cohorts, CSTF2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CSTF2 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CSTF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CSTF2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where CSTF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.826	0.207	.001	41	view →
HNSC	DFS	Quartile	IV	0.716	1.000	.003	22	view →
CCRCC	DFS	Median	All	0.697	1.000	.006	13	view →
PDAC	DFS	Quartile	III,IV	0.223	0.682	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CSTF2–LUAD (OS)

Open the LUAD breakdown →